英文名稱: Anti-STK38L mouse monoclonal antibody
技術規格
Background: |
The nuclear Dbf2-related kinases (NDR-1 and NDR-2) participate in the regulation of cell division and morphology, and may be implicated in tumor progression. NDR-1 and NDR-2 share 86% amino acid identity, but differ in their expression pattern. NDR-1 localizes to the nucleus, while NDR-2 exhibits punctate cytoplasmic distribution. Also, NDR-1 expression appears highest in spleen, lung and thymus, whereas NDR-2 shows highest expression in the gastrointestinal tract. However, both NDR-1 and NDR-2 are regulated by phosphorylation and by the Ca2+-binding protein S100B. NDR-1 and NDR-2 may also play a role in the HIV-1 life cycle. Both proteins are cleaved by the HIV-1 protease (PR), which inhibits their enzymatic activity and alters the subcellular localization of NDR-2. The genes encoding human NDR-1 and NDR-2 map to chromosomes 6p21 and 12p11.23, respectively. |
Applications: |
WB, IHC, IF |
Name of antibody: |
STK38L |
Immunogen: |
Fusion protein of human STK38L |
Full name: |
serine/threonine kinase 38 like (STK38L) |
Synonyms: |
NDR2 |
SwissProt: |
Q9Y2H1 |
IHC positive control: |
human colon tissue and human liver tissue; adenocarcinoma of human ovary tissue and human breast tissue |
IHC Recommend dilution: |
30-150 |
WB Predicted band size: |
54 kDa |
WB Positive control: |
HepG2, Hela, SVT2, A549, COS7, Jurkat, MDCK, PC12, MCF-7 cell lysates |
WB Recommended dilution: |
200-1000 |